Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cryptenamine is a mixture of 10 closely related hypotensive alkaloids extracted from the plant *Veratrum album*, including protoveratrines A and B, germitrine, neogermitrine, germerine, germidine, jervine, rubijervine, isorubijervine, and germbudine. It was used as an antihypertensive agent for the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects. The precise mechanism of action is not fully understood; however, it produces a marked depressor (blood pressure-lowering) effect when administered intravenously to hypertensive patients. Some evidence suggests that its action may be similar to atropine—acting as an antagonist at muscarinic acetylcholine receptors—though this remains experimental[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cryptenamine.